An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Evolv announced a new product, Evolv Grow, which they describe as an oral hair-growth supplement for men and women. They say it’s “powered by” something they call EV2 Peptide™, and that the supplement includes GHK-Cu, a molecule that has been talked about for skin and hair before. This is a commercial product launch — not a new medical treatment approved by regulators — so the news is mostly about a company releasing a consumer supplement. GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a small naturally occurring molecule that carries a copper ion. In plain terms: it’s a tiny piece of protein that likes to bind copper, and it’s been found in the body and in some skincare and haircare research. In some lab and animal studies and a few small human studies, GHK-Cu has been linked to things like wound healing, collagen production, and effects on hair follicles. “Peptide” here just means a short chain of amino acids — think of it as a very small protein-like ingredient. EV2 Peptide™ sounds like the company’s proprietary version or formulation, but the announcement doesn’t mean EV2 has been proven in large clinical trials. What the announcement actually shows is that Evolv is marketing an oral supplement containing GHK-Cu and their EV2 peptide. The press release is a product launch, not a controlled clinical trial report. It doesn’t provide details of peer-reviewed human studies showing how much hair growth users can expect, who was studied, or how long it takes to work. So the evidence in this announcement is marketing-level: it points to biological plausibility based on existing GHK-Cu research, but it doesn’t present new independent clinical data demonstrating effectiveness or safety at scale. Why it matters to a regular person: hair loss affects a lot of people and many seek non-prescription options. If you’re curious about supplements for hair health, a new product with a known molecule like GHK-Cu might be of interest. Some people prefer oral supplements to topical treatments, so an oral formulation could be convenient. However, because this is a consumer supplement, not a drug, the claims aren’t held to the same strict evidence standard as prescription medications for hair loss. Important caveats and risks: supplements are regulated differently from medicines. That means Evolv Grow can be sold without proving in large trials that it works or is safe long-term. GHK-Cu has some laboratory and small-scale human data, but broad, high-quality clinical proof is limited. Supplements can also interact with medications or cause side effects; people with medical conditions or those on prescriptions should check with a healthcare provider before trying new supplements. The press release doesn’t replace peer-reviewed studies, and it doesn’t mean EV2 Peptide™ is approved by regulators for treating hair loss. Bottom line: Evolv Grow is a new over-the-counter supplement that features GHK-Cu and a proprietary peptide; it may be worth watching, but the launch itself doesn’t prove it works — look for independent clinical evidence and talk to your doctor before trying it.
Source: StreetInsider